We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Snibe Showcases Maglumi X3 Fully Automatic CLIA System at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 12 Apr 2022

Snibe (Shenzhen, China) showcased its new fully automatic Chemiluminescence Immunoassay (CLIA) system at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, EUROMEDLAB 2022, in Munich, Germany. More...

EUROMEDLAB is the most influential platform in Europe where new ideas and technologies in laboratory diagnostics are shared and showcased.

At EUROMEDLAB 2022, Snibe demonstrated its new Maglumi X3 fully automatic CLIA system that is small but powerful, with a throughput of up to 200 tests per hour and a throughput per unit area is 294 tests per hour/m². One of the highest space efficiency CLIA analyzers, the Maglumi X3 combines one of the broadest automated CLIA test menus (181 parameters) and is compatible with all Maglumi reagents.

Its single reaction cup can avoid light pollution and increase cuvette utilization, while its integrated packaging can prevent the cuvette from sticking and destroying the cuvette wall. The MAGLUMI X3 features pipetting detection technologies such as liquid level, clot, and crash detection to ensure accurate and normal pipetting. It features the latest intelligent washing technology and bidirectional temperature control measurement to guarantee accurate and reliable results. With its advanced design, intelligent UI interface, user-friendly, easy, and convenient operation, the MAGLUMI X3 ensures excellent performance and is ideal for small and medium-sized hospitals and laboratories.

Related Links:
Snibe 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.